FAQ: Tonix Pharmaceuticals CEO's Participation in A.G.P. Healthcare Showcase and Company Overview
Summary
What was the purpose of Tonix Pharmaceuticals CEO’s participation in the A.G.P. Healthcare Showcase?
The purpose was to share strategic updates about Tonix Pharmaceuticals, including its integrated business model, marketed products, and advancing clinical pipeline, during a fireside chat at A.G.P.’s Annual Healthcare Company Showcase.
What is TNX-102 SL, and what is its significance?
TNX-102 SL is a product candidate for the management of fibromyalgia, for which two statistically significant phase 3 studies have been completed. It has been granted Fast Track designation by the FDA and is also being developed to treat acute stress reaction.
What recent contract did Tonix Pharmaceuticals announce with the U.S. Department of Defense?
Tonix announced a contract with the U.S. Department of Defense’s Defense Threat Reduction Agency for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections in military personnel.
Where can I find more information about Tonix Pharmaceuticals?
More information about Tonix Pharmaceuticals can be found on their website at www.TonixPharma.com or in the company’s newsroom at https://ibn.fm/TNXP.
What are some of the marketed products by Tonix Pharmaceuticals?
Tonix Medicines, the company’s commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
What is the focus of Tonix Pharmaceuticals’ development portfolio?
Tonix’s development portfolio is focused on central nervous system (CNS) disorders, immunology (including organ transplant rejection, autoimmunity, and cancer), rare disease, and infectious disease.
What is the significance of the FDA’s Fast Track designation for TNX-102 SL?
The FDA’s Fast Track designation for TNX-102 SL signifies that it is a promising treatment for fibromyalgia, potentially allowing for expedited review to bring it to market more quickly to address an unmet medical need.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 112102